Key result
Obesity and higher metabolic risk were associated with lower adiponectin protein expression in both abdominal adipose depots and inappropriately low leptin expression in subcutaneous adipose tissue.
Why the study?
Metabolic syndrome arises from abnormal adipose function with insulin resistance, prompting evaluation of adipokine levels in subcutaneous and visceral adipose tissues as factors reflecting lipid storage dysfunction.
How do adipokine signatures in subcutaneous and visceral adipose tissues differ between normal-weight and obese women with different metabolic profiles?
Cross-Sectional (n=50)
Yes
How do adipokine signatures in subcutaneous and visceral adipose tissues differ between normal-weight and obese women with different metabolic profiles?
Adipokine dysregulation, particularly low adiponectin and inappropriate leptin expression in subcutaneous adipose tissue, may be an early marker of obesity-related metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Does not support practice changes; hypothesis-generating for depot-specific adipokine patterns in obesity.
Introduction Metabolic syndrome arises from abnormal adipose function accompanied by insulin resistance. As early factors reflecting/impacting lipid storage dysfunction of adipose tissues, we sought to determine adipokine levels in subcutaneous and visceral adipose tissues (SAT and VAT). Material and methods Gene and protein expression of leptin, adiponectin, and resistin were analyzed in SAT and VAT of normal-weight and overweight/obese women, subclassified according to insulin resistance index, triglyceride, total-, LDL- and HDL-cholesterol levels into metabolically healthy and “at risk” groups. Results Compared with normal-weight women, obese women had higher serum leptin levels (P<0.05), as well as increased leptin gene and protein expression in VAT. Conversely, expression levels of leptin were lower in SAT of obese women, and minor in the SAT of “at risk” groups of women, compared with weight-matched healthy groups. In addition, lower adiponectin levels were detected in SAT of metabolically healthy obese women (P<0.01), and lower in SAT and VAT (P<0.05) of “at risk” obese women compared to healthy, obese women. Significant differences in resistin levels were only observed in obese women; resistin gene expression was higher in VAT and SAT of obese, compared to normal-weight women. However, higher gene expression was not consistent with protein expression of resistin. Conclusions Low adiponectin in both examined adipose tissues and inappropriate leptin expression levels in SAT appear to be important characteristics of obesity-related metabolic syndrome. Intriguingly, this adipokine dysregulation is primary seen in SAT, suggesting that endocrine dysfunction in this abdominal depot may be an early risk sign of metabolic syndrome.
No takes yet. Share an insight, caveat, or question.
Korać et al. (2021) conducted a cross-sectional in Obesity and Metabolic Syndrome (n=50). Obesity and metabolic risk vs. Normal-weight and metabolically healthy women was evaluated on Adipokine (leptin, adiponectin, resistin) gene and protein expression in subcutaneous and visceral adipose tissues (p=<0.05). Obesity and higher metabolic risk were associated with lower adiponectin protein expression in both abdominal adipose depots and inappropriately low leptin expression in subcutaneous adipose tissue.
Synapse has enriched 10 related papers. Consider them for comparative context: